

A Review of Therapeutic Potential of Psychedelic Compounds in Psychiatry
Abstract
The Substance Act of 1970 classified psychedelic drugs under Schedule I, hindering psychiatric research progress. However, recent years have seen a resurgence in psychedelic therapy interest, showing promise in treating various mental health conditions. Psychedelics like psilocybin and MDMA have demonstrated efficacy in conditions such as depression, PTSD, and substance use disorders. Safety and regulatory challenges persist, emphasizing the need for careful supervision to ensure their therapeutic use.
References
https://www.tandfonline.com/doi/full/10.31887/DCNS.2019.21.2/dnutt
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762%2823%2900146-1/fulltext
https://www.nature.com/articles/s41386-023-01656-7
https://www.theguardian.com/science/neurophilosophy/2014/sep/02/psychedelic-psychiatry
Refbacks
- There are currently no refbacks.